Amplification of the 3q chromosomal region as a specific marker in cervical cancer

Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of w...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of obstetrics and gynecology Vol. 213; no. 1; pp. 51.e1 - 51.e8
Main Authors Wright, Thomas C., Compagno, John, Romano, Patricia, Grazioli, Vittorio, Verma, Yogita, Kershnar, Eric, Tafas, Triantafyllos, Kilpatrick, Michael W.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2015
Subjects
Online AccessGet full text
ISSN0002-9378
1097-6868
1097-6868
DOI10.1016/j.ajog.2015.02.001

Cover

Loading…
Abstract Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal. These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.
AbstractList Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal. These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.
Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.OBJECTIVEChromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.STUDY DESIGNResidual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal.RESULTSUsing the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal.These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.CONCLUSIONThese data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.
Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal. These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.
Objective Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Study Design Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Results Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal. Conclusion These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.
Author Wright, Thomas C.
Tafas, Triantafyllos
Romano, Patricia
Grazioli, Vittorio
Kilpatrick, Michael W.
Verma, Yogita
Compagno, John
Kershnar, Eric
Author_xml – sequence: 1
  givenname: Thomas C.
  surname: Wright
  fullname: Wright, Thomas C.
  organization: Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY, and Research Pathology Associates, Irvington, NY
– sequence: 2
  givenname: John
  surname: Compagno
  fullname: Compagno, John
  organization: West Coast Pathology Laboratories, Hercules, CA
– sequence: 3
  givenname: Patricia
  surname: Romano
  fullname: Romano, Patricia
  organization: Shiel Medical Laboratory, Brooklyn, NY
– sequence: 4
  givenname: Vittorio
  surname: Grazioli
  fullname: Grazioli, Vittorio
  organization: Centro Diagnostico Italiano, Milan, Italy
– sequence: 5
  givenname: Yogita
  surname: Verma
  fullname: Verma, Yogita
  organization: Ikonisys Inc, New Haven, CT
– sequence: 6
  givenname: Eric
  surname: Kershnar
  fullname: Kershnar, Eric
  organization: Ikonisys Inc, New Haven, CT
– sequence: 7
  givenname: Triantafyllos
  surname: Tafas
  fullname: Tafas, Triantafyllos
  organization: Ikonisys Inc, New Haven, CT
– sequence: 8
  givenname: Michael W.
  surname: Kilpatrick
  fullname: Kilpatrick, Michael W.
  email: Michael.kilpatrick@ikonisys.com
  organization: Ikonisys Inc, New Haven, CT
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25659466$$D View this record in MEDLINE/PubMed
BookMark eNqFkl1r3SAch2V0rKfdvsAuhpe7SeZLNDrGoJS9QaHQbtdizD-taRJPNafQbz_taW8K665U_D0_5dEjdLCEBRB6T0lNCZWfxtqO4apmhIqasJoQ-gptKNFtJZVUB2hDCGGV5q06REcpjWXJNHuDDpmQQjdSbtDFybyd_OCdXX1YcBjweg2Y32J3HcMcUpjthCNclU2bsMVpC67k8WzjDUTsF-wg3uWCCTu75Plb9HqwU4J3j-Mx-vP92-_Tn9XZ-Y9fpydnlZNSrZV0jvO244xAT2zTdapvLRBuO8WUBUuEprZrh65vmCDUct3LXquGaQEtt4Ifo4_73m0MtztIq5l9cjBNdoGwS4ZKTYVWvGlz9MNjdNfN0Jtt9Pn69-bJQw6ofcDFkFKEwTi_PihZo_WTocQU5WY0Rbkpyg1hJivPKHuGPrW_CH3ZQ5AF3XmIJjkP2V7vI7jV9MG_jH99hrvJL-UNbuAe0hh2ccnqDTUpA-ayvHz5B1Rkmori7vO_C_53-l-5XcHO
CitedBy_id crossref_primary_10_3389_fonc_2022_887139
crossref_primary_10_1111_1759_7714_15045
crossref_primary_10_1186_s12885_016_2739_6
crossref_primary_10_3390_microarrays4020287
crossref_primary_10_1038_s41598_019_45477_5
crossref_primary_10_1080_14737159_2020_1835472
crossref_primary_10_1093_jjco_hyab109
crossref_primary_10_1186_s12916_022_02630_8
crossref_primary_10_1002_gcc_22818
crossref_primary_10_1016_j_currproblcancer_2020_100567
crossref_primary_10_1080_14737159_2016_1217157
crossref_primary_10_1038_s43018_021_00250_4
Cites_doi 10.7326/0003-4819-132-10-200005160-00009
10.1016/j.hrtlng.2013.01.006
10.1016/S0002-9440(10)63498-0
10.1016/j.ygyno.2013.06.005
10.1016/S0140-6736(04)17354-6
10.1097/AOG.0b013e31818f5008
10.1093/jnci/djq562
10.2353/jmoldx.2007.070007
10.1016/j.ygyno.2008.01.040
10.1093/jnci/92.5.397
10.1016/j.ajog.2004.03.055
10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y
10.1016/j.ygyno.2009.03.031
10.1002/path.2070
10.1016/S0002-9440(10)62341-3
10.1097/IGC.0b013e31825104bd
10.2353/ajpath.2009.090122
10.1016/S1470-2045(11)70188-7
10.1371/journal.pone.0039101
10.1016/j.ajog.2009.12.016
ContentType Journal Article
Copyright 2015 Elsevier Inc.
Elsevier Inc.
Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ajog.2015.02.001
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6868
EndPage 51.e8
ExternalDocumentID 25659466
10_1016_j_ajog_2015_02_001
S0002937815001155
1_s2_0_S0002937815001155
Genre Journal Article
GroupedDBID ---
--K
--M
-ET
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1CY
1P~
1~.
1~5
23M
2KS
354
3O-
4.4
457
4CK
4G.
53G
5GY
5RE
5VS
6J9
7-5
85S
8F7
8P~
AAEDT
AAEDW
AAIKC
AAIKJ
AAKOC
AALRI
AAMNW
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYJJ
AAYWO
ABBQC
ABCQX
ABDPE
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABOCM
ABPMR
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFCHL
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGNAY
AGQPQ
AGUBO
AGYEJ
AHDLI
AI.
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
C45
C5W
CAG
COF
CS3
EBS
EFJIC
EFKBS
EJD
EO8
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
LPU
M41
MO0
N4W
N9A
NEJ
NQ-
O-L
O9-
OAUVE
OBH
OCB
OGEVE
OHH
OHT
OMK
OQ.
OVD
P-8
P-9
P2P
PC.
PH~
Q38
R2-
ROL
RPZ
RXW
SDF
SEL
SES
SEW
SJN
SPCBC
SSH
SSZ
T5K
TAE
TEORI
TWZ
UDS
UGJ
UHB
UHS
UHU
UKR
UNMZH
UV1
VH1
VVN
WH7
WOQ
WOW
X6Y
X7M
XFW
YFH
YOC
YYQ
YZZ
Z5R
ZGI
ZXP
ZY1
~G-
~H1
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
NCXOZ
RIG
AAIAV
ABLVK
ABYKQ
ADOJD
AFDAS
AHPSJ
AJBFU
EFLBG
G8K
LCYCR
ZA5
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c668t-6cc337b320ed0a4bb8d7ae03ab828aea0591ab7fbd42501a39d6d984295e73a53
IEDL.DBID .~1
ISSN 0002-9378
1097-6868
IngestDate Thu Jul 10 19:33:51 EDT 2025
Wed Feb 19 02:42:34 EST 2025
Tue Jul 01 00:55:55 EDT 2025
Thu Apr 24 22:59:16 EDT 2025
Fri Feb 23 02:29:19 EST 2024
Sun Feb 23 10:18:58 EST 2025
Tue Aug 26 17:15:27 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords cervical intraepithelial neoplasia grades 2 and 3
low-grade squamous intraepithelial lesion
high-risk human papillomavirus
3q gain
atypical squamous cells of undetermined significance
squamous cell carcinomas
high-grade squamous intraepithelial lesion
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c668t-6cc337b320ed0a4bb8d7ae03ab828aea0591ab7fbd42501a39d6d984295e73a53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25659466
PQID 1691598347
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1691598347
pubmed_primary_25659466
crossref_citationtrail_10_1016_j_ajog_2015_02_001
crossref_primary_10_1016_j_ajog_2015_02_001
elsevier_sciencedirect_doi_10_1016_j_ajog_2015_02_001
elsevier_clinicalkeyesjournals_1_s2_0_S0002937815001155
elsevier_clinicalkey_doi_10_1016_j_ajog_2015_02_001
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-07-01
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of obstetrics and gynecology
PublicationTitleAlternate Am J Obstet Gynecol
PublicationYear 2015
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Schiffman, Wentzensen, Wacholder (bib2) 2011; 103
Hopman, Theelen, Hommelberg (bib8) 2006; 210
Jalali, Herzog, Dziura, Walat, Kilpatrick (bib18) 2010; 202
Nanda, McCrory, Myers (bib1) 2000; 132
Luhn, Houldsworth, Cahill (bib15) 2013; 130
Rodolakis, Biliatis, Symiakaki (bib21) 2012; 22
Heselmeyer-Haddad, Janz, Castle (bib14) 2003; 163
Andersson, Sowjanya, Wangsa (bib11) 2009; 175
Heselmeyer-Haddad, Sommerfeld, White (bib10) 2005; 166
Castle, Stoler, Wright, Sharma, Wright, Behrens (bib19) 2011; 12
Heselmeyer, Macville, Schrock (bib7) 1997; 19
Sokolova, Algeciras-Schimnich, Song (bib9) 2007; 9
Kilpatrick, Tafas, Evans (bib17) 2004; 190
Caraway, Khanna, Dawlett (bib6) 2008
Moscicki, Shiboski, Hills (bib3) 2004; 364
Castle, Schiffman, Wheeler, Solomon (bib5) 2009; 113
Parshall (bib16) 2013; 42
Manos, Wright, Lewis (bib13) 1989
Heitmann, Lankachandra, Wall (bib20) 2012; 7
Koutsky (bib4) 2000; 92
Seppo, Jalali, Babkowski (bib12) 2009; 114
Heselmeyer (10.1016/j.ajog.2015.02.001_bib7) 1997; 19
Heselmeyer-Haddad (10.1016/j.ajog.2015.02.001_bib10) 2005; 166
Manos (10.1016/j.ajog.2015.02.001_bib13) 1989
Schiffman (10.1016/j.ajog.2015.02.001_bib2) 2011; 103
Moscicki (10.1016/j.ajog.2015.02.001_bib3) 2004; 364
Seppo (10.1016/j.ajog.2015.02.001_bib12) 2009; 114
Castle (10.1016/j.ajog.2015.02.001_bib19) 2011; 12
Hopman (10.1016/j.ajog.2015.02.001_bib8) 2006; 210
Castle (10.1016/j.ajog.2015.02.001_bib5) 2009; 113
Nanda (10.1016/j.ajog.2015.02.001_bib1) 2000; 132
Jalali (10.1016/j.ajog.2015.02.001_bib18) 2010; 202
Andersson (10.1016/j.ajog.2015.02.001_bib11) 2009; 175
Heitmann (10.1016/j.ajog.2015.02.001_bib20) 2012; 7
Rodolakis (10.1016/j.ajog.2015.02.001_bib21) 2012; 22
Luhn (10.1016/j.ajog.2015.02.001_bib15) 2013; 130
Kilpatrick (10.1016/j.ajog.2015.02.001_bib17) 2004; 190
Sokolova (10.1016/j.ajog.2015.02.001_bib9) 2007; 9
Parshall (10.1016/j.ajog.2015.02.001_bib16) 2013; 42
Caraway (10.1016/j.ajog.2015.02.001_bib6) 2008
Koutsky (10.1016/j.ajog.2015.02.001_bib4) 2000; 92
Heselmeyer-Haddad (10.1016/j.ajog.2015.02.001_bib14) 2003; 163
References_xml – volume: 113
  start-page: 18
  year: 2009
  end-page: 25
  ident: bib5
  article-title: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2
  publication-title: Obstet Gynecol
– volume: 9
  start-page: 604
  year: 2007
  end-page: 611
  ident: bib9
  article-title: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens
  publication-title: J Mol Diag
– volume: 190
  start-page: 1571
  year: 2004
  end-page: 1581
  ident: bib17
  article-title: Automated detection of rara fetal cells in maternal blood: eliminating the false-positive XY signals in XX pregnancies
  publication-title: Am J Obstet Gynecol
– volume: 19
  start-page: 233
  year: 1997
  end-page: 240
  ident: bib7
  article-title: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q
  publication-title: Genes Chromosom Cancer
– volume: 130
  start-page: 595
  year: 2013
  end-page: 600
  ident: bib15
  article-title: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results
  publication-title: Gynecol Oncol
– volume: 7
  start-page: e39101
  year: 2012
  ident: bib20
  article-title: 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study
  publication-title: PLoS One
– volume: 163
  start-page: 1405
  year: 2003
  end-page: 1416
  ident: bib14
  article-title: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia
  publication-title: Am J Pathol
– volume: 210
  start-page: 412
  year: 2006
  end-page: 419
  ident: bib8
  article-title: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer
  publication-title: J Pathol
– volume: 202
  start-page: 581.e1
  year: 2010
  end-page: 581.e5
  ident: bib18
  article-title: Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding
  publication-title: Am J Obstet Gynecol
– volume: 166
  start-page: 1229
  year: 2005
  end-page: 1238
  ident: bib10
  article-title: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer
  publication-title: Am J Pathol
– volume: 22
  start-page: 742
  year: 2012
  end-page: 747
  ident: bib21
  article-title: Role of chromosome 3q26 in predicting progression of cervical dysplasia
  publication-title: Int J Gynecol Cancer
– volume: 364
  start-page: 1678
  year: 2004
  end-page: 1683
  ident: bib3
  article-title: Regression of low-grade squamous intra-epithelial lesions in young women
  publication-title: Lancet
– volume: 12
  start-page: 880
  year: 2011
  end-page: 890
  ident: bib19
  article-title: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
  publication-title: Lancet Oncol
– volume: 175
  start-page: 1831
  year: 2009
  end-page: 1847
  ident: bib11
  article-title: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears
  publication-title: Am J Pathol
– volume: 103
  start-page: 368
  year: 2011
  end-page: 383
  ident: bib2
  article-title: Human papillomavirus testing in the prevention of cervical cancer
  publication-title: J Natl Cancer Inst
– year: 2008
  ident: bib6
  article-title: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma
  publication-title: Gynecol Oncol
– volume: 114
  start-page: 80
  year: 2009
  end-page: 83
  ident: bib12
  article-title: Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix
  publication-title: Gynecol Oncol
– start-page: 209
  year: 1989
  end-page: 214
  ident: bib13
  article-title: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses
  publication-title: Molecular diagnostics of human cancer
– volume: 92
  start-page: 397
  year: 2000
  end-page: 402
  ident: bib4
  article-title: The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial
  publication-title: J Natl Cancer Inst
– volume: 42
  start-page: 221
  year: 2013
  end-page: 226
  ident: bib16
  article-title: Unpacking the 2×2 table
  publication-title: Heart Lung
– volume: 132
  start-page: 810
  year: 2000
  end-page: 819
  ident: bib1
  article-title: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review
  publication-title: Ann Intern Med
– volume: 132
  start-page: 810
  year: 2000
  ident: 10.1016/j.ajog.2015.02.001_bib1
  article-title: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-132-10-200005160-00009
– volume: 42
  start-page: 221
  year: 2013
  ident: 10.1016/j.ajog.2015.02.001_bib16
  article-title: Unpacking the 2×2 table
  publication-title: Heart Lung
  doi: 10.1016/j.hrtlng.2013.01.006
– volume: 163
  start-page: 1405
  year: 2003
  ident: 10.1016/j.ajog.2015.02.001_bib14
  article-title: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)63498-0
– volume: 130
  start-page: 595
  year: 2013
  ident: 10.1016/j.ajog.2015.02.001_bib15
  article-title: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2013.06.005
– volume: 364
  start-page: 1678
  year: 2004
  ident: 10.1016/j.ajog.2015.02.001_bib3
  article-title: Regression of low-grade squamous intra-epithelial lesions in young women
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)17354-6
– volume: 113
  start-page: 18
  year: 2009
  ident: 10.1016/j.ajog.2015.02.001_bib5
  article-title: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2
  publication-title: Obstet Gynecol
  doi: 10.1097/AOG.0b013e31818f5008
– volume: 103
  start-page: 368
  year: 2011
  ident: 10.1016/j.ajog.2015.02.001_bib2
  article-title: Human papillomavirus testing in the prevention of cervical cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq562
– volume: 9
  start-page: 604
  year: 2007
  ident: 10.1016/j.ajog.2015.02.001_bib9
  article-title: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens
  publication-title: J Mol Diag
  doi: 10.2353/jmoldx.2007.070007
– year: 2008
  ident: 10.1016/j.ajog.2015.02.001_bib6
  article-title: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2008.01.040
– start-page: 209
  year: 1989
  ident: 10.1016/j.ajog.2015.02.001_bib13
  article-title: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses
– volume: 92
  start-page: 397
  year: 2000
  ident: 10.1016/j.ajog.2015.02.001_bib4
  article-title: The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.5.397
– volume: 190
  start-page: 1571
  year: 2004
  ident: 10.1016/j.ajog.2015.02.001_bib17
  article-title: Automated detection of rara fetal cells in maternal blood: eliminating the false-positive XY signals in XX pregnancies
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/j.ajog.2004.03.055
– volume: 19
  start-page: 233
  year: 1997
  ident: 10.1016/j.ajog.2015.02.001_bib7
  article-title: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q
  publication-title: Genes Chromosom Cancer
  doi: 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y
– volume: 114
  start-page: 80
  year: 2009
  ident: 10.1016/j.ajog.2015.02.001_bib12
  article-title: Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.03.031
– volume: 210
  start-page: 412
  year: 2006
  ident: 10.1016/j.ajog.2015.02.001_bib8
  article-title: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer
  publication-title: J Pathol
  doi: 10.1002/path.2070
– volume: 166
  start-page: 1229
  year: 2005
  ident: 10.1016/j.ajog.2015.02.001_bib10
  article-title: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)62341-3
– volume: 22
  start-page: 742
  year: 2012
  ident: 10.1016/j.ajog.2015.02.001_bib21
  article-title: Role of chromosome 3q26 in predicting progression of cervical dysplasia
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0b013e31825104bd
– volume: 175
  start-page: 1831
  year: 2009
  ident: 10.1016/j.ajog.2015.02.001_bib11
  article-title: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2009.090122
– volume: 12
  start-page: 880
  year: 2011
  ident: 10.1016/j.ajog.2015.02.001_bib19
  article-title: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70188-7
– volume: 7
  start-page: e39101
  year: 2012
  ident: 10.1016/j.ajog.2015.02.001_bib20
  article-title: 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0039101
– volume: 202
  start-page: 581.e1
  year: 2010
  ident: 10.1016/j.ajog.2015.02.001_bib18
  article-title: Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/j.ajog.2009.12.016
SSID ssj0002292
Score 2.256563
Snippet Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix....
Objective Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 51.e1
SubjectTerms 3q gain
Algorithms
Atypical Squamous Cells of the Cervix
atypical squamous cells of undetermined significance
Cervical Intraepithelial Neoplasia - genetics
cervical intraepithelial neoplasia grades 2 and 3
Chromosomes, Human, Pair 3 - genetics
DNA Probes
Female
Gene Dosage
high-grade squamous intraepithelial lesion
high-risk human papillomavirus
Humans
In Situ Hybridization, Fluorescence
low-grade squamous intraepithelial lesion
Obstetrics and Gynecology
Precancerous Conditions - genetics
Sensitivity and Specificity
squamous cell carcinomas
Squamous Intraepithelial Lesions of the Cervix - genetics
Uterine Cervical Neoplasms - genetics
Title Amplification of the 3q chromosomal region as a specific marker in cervical cancer
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0002937815001155
https://www.clinicalkey.es/playcontent/1-s2.0-S0002937815001155
https://dx.doi.org/10.1016/j.ajog.2015.02.001
https://www.ncbi.nlm.nih.gov/pubmed/25659466
https://www.proquest.com/docview/1691598347
Volume 213
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRUJcEG-WR2UkbijUiRM7Oa4qqgXUHhCVerPGj4WtaFI222t_e2cSZxGCFoljkhk5mcyMPyffjAHeBm1cpQqX5RppgZIrk7mQY4ZDdxZHWkOz6qNjvTgpP51WpztwMNXCMK0y5f4xpw_ZOp3ZT9bcv1ituMZX0lxlaoI0jGu40Jy715FPv7_6RfMoiqaYIDBLp8KZkeOFZ903pndVY9_O_KbJ6SbwOUxChw_gfkKPYj7e4EPYie0juHuU_o8_hi9zJogv03c40S0F4Tuhfgr_nWl3fXdO2rwXA13EXqDgQkuWF-dM01mLVSv8kD1IzrNDrJ_AyeGHrweLLO2akHmt602mvVfKOFXIGCSWztXBYJQKHS2uMCLhqRydWbpA4SpzVE3QoalpXqqiUVipp7Dbdm18DsIHr6NcShWMKoP0GOuKAEodlSqxKYsZ5JO5rE8txXlnix924o6dWTaxZRNbWTCBbgbvtjoXY0ONW6XV9BbsVCpKyc1Svr9Vy_xNK_YpPnub254k7R8-NINqq_mbG_5zxDeTi1iKT_7pgm3sLmkk3RBirFVpZvBs9J3tcxPcrLi__4v_HPUl3OOjkT38CnY368v4mjDSxu0NQbAHd-YfPy-OrwGfBg3R
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7RRWp7qeh7Sx-u1FsV4cRxnBxXqGgp7B4qkLhZfm1ZVBLYLP-fmcRZCbVQiWvskZPJPL7E34wBvvlCWSkym6SFwQ-UVKjE-tQkpuvOYlGqa1Y9mxfT0_znmTzbgv2hFoZolTH29zG9i9bxyl7U5t7Vckk1vhxzlSoR0hCukU9gm7pT5SPYnhweTeebgJxlVTagYBKItTM9zctcNL-J4SX71p3pffnpPvzZ5aGDHXgRASSb9Pf4ErZC_QqezuIW-Wv4NSGO-CL-imPNgiHEY-KauXNi3rXNJUrTcQw4aFpmGNVa0nx2SUydFVvWzHUBBOc5sonVGzg9-HGyP03iwQmJK4pynRTOCaGsyHjw3OTWll6ZwIWx-H1lgkFIlRqrFtajx_LUiMoXvioxNcmghJHiLYzqpg7vgTnvisAXXHglcs-dCaVEjFIGIXJT5dkY0kFd2sWu4nS4xR890McuNKlYk4o1z4hDN4bvG5mrvqfGg7PF8Bb0UC2K8U1jyH9QSv1LKrTRRVud6hZn6r_MaAxyI3nHEv-74tfBRDS6KO27mDo0N7hSUSFoLEWuxvCut53NcyPilNTi_8MjV_0Cz6Yns2N9fDg_2oXnNNKTiT_CaL26CZ8QMq3t5-gSt9htEII
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amplification+of+the+3q+chromosomal+region+as+a+specific+marker+in+cervical+cancer&rft.jtitle=American+journal+of+obstetrics+and+gynecology&rft.au=Wright%2C+Thomas+C.&rft.au=Compagno%2C+John&rft.au=Romano%2C+Patricia&rft.au=Grazioli%2C+Vittorio&rft.date=2015-07-01&rft.issn=0002-9378&rft.volume=213&rft.issue=1&rft.spage=51&rft.epage=51.e8&rft_id=info:doi/10.1016%2Fj.ajog.2015.02.001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ajog_2015_02_001
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029378%2FS0002937814X00098%2Fcov150h.gif